We are international
Donate
• videos TEXT SIZE   

ASH 2007 WEBCAST

We are pleased to present these overviews of the 49th Annual American Society of Hematology Meeting (ASH) that was held in Atlanta, Georgia from December 8-11, 2007.

ASH 2007
previous     next      view all

Newly Diagnosed Myeloma
Dr. Ludwig - Thalidomide-Dexamethasone vs. Melphalan-Prednisone as First Line Treatment in Elderly Patients with Multiple Myeloma
Heinz Ludwig, MD
Wilhelminenspital der Stadt Wein
Vienna, Austria
Member, IMF Board of Scientific Advisors

Dr. Zonder - Superiority of Lenalidomide (Len) Plus High-Dose Dexamethasone (HD) Compared to HD Alone as Treatment of Newly-Diagnosed Multiple Myeloma (NDMM): Results of the Randomized, Double-Blinded, Placebo-Controlled SWOG Trial S0232
Jeffrey A. Zonder, MD
Karmanos Cancer Institute
Detroit, Michigan

Dr. Waage - Melphalan-Prednisone-Thalidomide to Newly Diagnosed Patients with Multiple Myeloma: A Placebo Controlled Randomised Phase 3 Trial
Anders Waage, MD
University Hospital
Trondheim, Norway

Relapsed/Refractory Myeloma
Dr. San Miguel - Dexamethasone Dose Adjustments Seem To Result in Better Efficacy and Improved Tolerability in Patients with Relapsed/Refractory Multiple Myeloma Who Are Treated with Lenalidomide/Dexamethasone (MM009/010 Sub-Analysis)
Jesús San Miguel, MD
Hospital Clinico Universitario
Universidad de Salamanca
Salamanca, Spain
Member, IMF Board of Scientific Advisors

Dr. Jagannath - Updated Survival Analyses after Prolonged Follow-Up of the Phase 2, Multicenter CREST Study of Bortezomib in Relapsed or Refractory Multiple Myeloma
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY
Member, IMF Board of Scientific Advisors

Dr. Bladé - The Prolonged Time to Progression with Pegylated Liposomal Doxorubicin + Bortezomib Versus Bortezomib Alone in Relapsed or Refractory Multiple Myeloma Is Unaffected by Extent of Prior Therapy or Previous Anthracycline Exposure
Joan Bladé, MD
Hospital Clinic
Hematology
Barcelona, Spain
Member, IMF Board of Scientific Advisors

Dr. Davies - The Combination of Velcade, Idarubicin and Melphalan (VIM) Demonstrates Significant Clinical Activity in Relapsed/Refractory Myeloma Patients
Faith E. Davies, MD
The Royal Marsden NHS Foundation Trust
Sutton, Surrey, UK
Member, IMF Board of Scientific Advisors

Dr. Orlowski: Early Normalization of Serum Free Light Chain Is Associated with Prolonged Time to Progression Following Bortezomib Pegylated Liposomal Doxorubicin Treatment of Relapsed/Refractory Multiple Myeloma
Robert Z. Orlowski, MD
MD Anderson Cancer Center
Houston, Texas

Dr. Jakubowiak - A Multiple Myeloma Research Consortium (MMRC) Multicenter Phase I Trial of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (MM): Updated Results
Andrzej Jakubowiak, MD
University of Michigan Cancer Center
Ann Arbor, MI

New Agents
Dr. Richardson - Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation
Paul Richardson, MD
Jerome Lipper Myeloma Center
Dana Farber Cancer Institute
Boston, MA
Member, IMF Board of Scientific Advisors

previous     next      view all